An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer.

摘要: Temozolomide is a novel oral alkylating agent that has schedule-dependent clinical activity in human malignant glioma and metastatic melanoma. Little known about the efficacy of temozolomide treatment canine solid cancers, where broad range dosages have been used but no maximally tolerated dose (MTD) had established. The aim this open-label, dose-escalating study was to determine MTD dose-limiting toxicity (DLT) single cycle dogs with advanced tumours. administered as 5-days course starting at 70 mg/m2 , using escalation 10 increments 3 per level. established based on number experiencing DLT assessed after 1 cycle. Safety evaluation performed days dosing. Thirty-three client-owned were enrolled. 150 most frequent adverse events (AEs) hematologic hepatic, followed by gastrointestinal, majority being self-resolving mild grade. VCOG grade hepatic 4 thrombocytopenia defined DLTs 160 . A subcohort received multiple doses 4-week cumulative documented. Conclusions define when given once daily over 5 days. Future trials its are warranted.